Gyre Therapeutics (NASDAQ:GYRE) Sees Unusually-High Trading Volume – What’s Next?

Shares of Gyre Therapeutics, Inc. (NASDAQ:GYRE) saw unusually-high trading volume on Friday . Approximately 38,827 shares were traded during mid-day trading, a decline of 47% from the previous session’s volume of 73,103 shares.The stock last traded at $9.96 and had previously closed at $9.78.

Gyre Therapeutics Stock Down 1.4 %

The stock has a fifty day moving average price of $13.07 and a 200 day moving average price of $12.59.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Bank of New York Mellon Corp purchased a new stake in shares of Gyre Therapeutics in the second quarter valued at $218,000. Rhumbline Advisers purchased a new stake in Gyre Therapeutics in the 2nd quarter worth about $123,000. WINTON GROUP Ltd bought a new stake in Gyre Therapeutics in the second quarter worth about $220,000. Renaissance Technologies LLC bought a new stake in Gyre Therapeutics in the second quarter worth about $166,000. Finally, Charles Schwab Investment Management Inc. boosted its position in shares of Gyre Therapeutics by 392.2% during the third quarter. Charles Schwab Investment Management Inc. now owns 113,648 shares of the company’s stock valued at $1,425,000 after buying an additional 90,557 shares during the period. 23.99% of the stock is owned by hedge funds and other institutional investors.

Gyre Therapeutics Company Profile

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.